Omega Diagnostics’ share price has soared. Here are 5 things you should know

The Omega Diagnostics share price has become one of the market’s hottest stocks, but does the business have what it takes to hit the big time?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Omega Diagnostics (LSE: ODX) share price has surged in value this year. This positive performance may have attracted some investors to the company ahead of further gains.

With that in mind, today I’m going to take a look at the five things you should know before buying into the business. 

Omega Diagnostics share price: need-to-know

The coronavirus pandemic has been a boon for Omega. The company is planning to produce as many as five different types of Covid-19 tests.

The self-test usability study for one of these, the AbC-19 Rapid Test, was completed last weekend. This put the product one step closer to coming to market. 

As well as the Rapid antibody Test, at the beginning of September, Omega’s Mologic Covid-19 lateral flow antibody test was awarded its CE Mark. This quality marking means the business can now start marketing and selling the product.

These Covid tests are not the only strings to Omega’s bow. The group has three operating segments. As well as the coronavirus testing segment, there’s a division specialising in allergies and food intolerances. The third segment provides HIV testing equipment. This provides some diversification for the business. 

Unfortunately, the company remains in its early stages. It’s not yet self-sufficient, which could be a red flag for investors looking at the Omega Diagnostics share price.

Earlier this year, the group raised £11m from investors to scale up production. While demand for the company’s products will provide much-needed cash flow, I wouldn’t rule out another cash raise in future as the business finds its feet. 

Still, despite this drawback, it’s clear the business has tremendous potential.

Financial broker finnCap reckons Omega could ultimately be looking at £8m-£12m of revenue from its food intolerance testing business and £37m in revenues from Covid test sales. The group’s HIV test, VISITECT CD4, could be worth between £45m to £75m. 

100% upside?

Based on these projections, the Omega Diagnostics share price looks cheap after its recent performance.

In the best case, the projections above suggest the business has the potential to generate £124m in annual revenues. Quest Diagnostics Inc is one of the largest testing companies in the world. And that stock is currently trading at a multiple of two times sales.

Based on this, it’s not unreasonable to suggest Omega could be worth as much as £248m in the best-case scenario. 

However, I should stress this is the best-case scenario. The company is still finding its way, and a lot could wrong between now and annual sales of £124m.

That said, it’s clear there’s a tremendous amount of potential here. With upside potential as much as 100%, investors could be well rewarded if the company gets everything right.

Therefore, the best solution may be to own the stock as part of a diversified portfolio. Doing so would minimise downside risk while providing exposure to profits if the Omega Diagnostics share price continues to surge in value.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Should I follow Warren Buffett and sell my favourite shares?

Billionaire US investor Warren Buffett has been selling tons of Apple shares and other stocks of businesses he thinks are…

Read more »